Beijing Sl Pharma Co Ltd   Report issue

For profit Phase 2
Founded: Shanghai China (1994)
Status: Left NME R&D (2000)

Organization Overview

First Clinical Trial
2015
NCT02465580
First Marketed Drug
2018
febuxostat (uloric)
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Beijing ShuangLu Pharmaceutical Co., Ltd. | BEIJING SL PHARMA CO LTD

Active Ingredients

Marketed Drugs (1)

febuxostat (uloric) (2018)

Drugs in Phase 2 Trials (4)

aldesleukin (proleukin) (3 trials)

folic acid (1 trial)

loxoprofen (1 trial)

naltrexone (revia) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Sjogren's Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4